Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

Filiberto Cedeno-Laurent; Elisha M. Singer; Maria Wysocka; Bernice M. Benoit; Carmela C. Vittorio; Ellen J. Kim; Gil Yosipovitch; Alain H. Rook

doi:10.1016/j.clim.2015.02.014

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

Filiberto Cedeno-Laurent, Elisha M. Singer, Maria Wysocka, Bernice M. Benoit, Carmela C. Vittorio, Ellen J. Kim, Gil Yosipovitch, Alain H. Rook

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.

Original language	English (US)
Pages (from-to)	1-7
Number of pages	7
Journal	Clinical Immunology
Volume	158
Issue number	1
DOIs	https://doi.org/10.1016/j.clim.2015.02.014
State	Published - May 1 2015
Externally published	Yes

Keywords

CTCL
IL-31
Immunotherapy
Pruritus

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.clim.2015.02.014

Fingerprint Dive into the research topics of 'Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities'. Together they form a unique fingerprint.

Cite this

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. / Cedeno-Laurent, Filiberto; Singer, Elisha M.; Wysocka, Maria; Benoit, Bernice M.; Vittorio, Carmela C.; Kim, Ellen J.; Yosipovitch, Gil; Rook, Alain H.

In: Clinical Immunology, Vol. 158, No. 1, 01.05.2015, p. 1-7.

Research output: Contribution to journal › Article › peer-review

@article{7df4d9783ed948d99261a60ffe6c713a,

title = "Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities",

abstract = "Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.",

keywords = "CTCL, IL-31, Immunotherapy, Pruritus",

author = "Filiberto Cedeno-Laurent and Singer, {Elisha M.} and Maria Wysocka and Benoit, {Bernice M.} and Vittorio, {Carmela C.} and Kim, {Ellen J.} and Gil Yosipovitch and Rook, {Alain H.}",

note = "Funding Information: This work was supported by NCI grant R01CA122569 and a Translation Research Grant from the Leukemia and Lymphoma Society (to AHR). Publisher Copyright: {\textcopyright} 2015 Elsevier Inc. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.",

year = "2015",

month = may,

day = "1",

doi = "10.1016/j.clim.2015.02.014",

language = "English (US)",

volume = "158",

pages = "1--7",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

AU - Cedeno-Laurent, Filiberto

AU - Singer, Elisha M.

AU - Wysocka, Maria

AU - Benoit, Bernice M.

AU - Vittorio, Carmela C.

AU - Kim, Ellen J.

AU - Yosipovitch, Gil

AU - Rook, Alain H.

N1 - Funding Information: This work was supported by NCI grant R01CA122569 and a Translation Research Grant from the Leukemia and Lymphoma Society (to AHR). Publisher Copyright: © 2015 Elsevier Inc. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.

AB - Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.

KW - CTCL

KW - IL-31

KW - Immunotherapy

KW - Pruritus

UR - http://www.scopus.com/inward/record.url?scp=84924985426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924985426&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2015.02.014

DO - 10.1016/j.clim.2015.02.014

M3 - Article

C2 - 25762519

AN - SCOPUS:84924985426

VL - 158

SP - 1

EP - 7

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this